Vetoryl 10 mg hard capsules for dogs

Pays: Irlande

Langue: anglais

Source: HPRA (Health Products Regulatory Authority)

Achète-le

Ingrédients actifs:

Trilostane

Disponible depuis:

Dechra Ltd

Code ATC:

QH02CA01

DCI (Dénomination commune internationale):

Trilostane

Dosage:

10 Milligrams per capsule

forme pharmaceutique:

Capsule, hard

Type d'ordonnance:

POM: Prescription Only Medicine as defined in relevant national legislation

Groupe thérapeutique:

Dogs

Domaine thérapeutique:

trilostane

indications thérapeutiques:

Hormone

Statut de autorisation:

Authorised

Date de l'autorisation:

2010-10-01

Résumé des caractéristiques du produit

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Vetoryl 10 mg hard capsules for dogs.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
3 PHARMACEUTICAL FORM
Hard capsule.
Ivory body and black cap with the capsule strength printed on the body
of the capsule.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
In dogs: for the treatment of pituitary-dependent and
adrenal-dependent hyperadrenocorticism (Cushing’s disease and
syndrome).
4.3 CONTRAINDICATIONS
Do not use in animals suffering from primary hepatic disease and/or
renal insufficiency.
Do not use in dogs weighing less than 3 kg.
Do not use where there is suspected hypersensitivity to the active
substance or to any of the excipients.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
An accurate diagnosis of hyperadrenocorticism is essential.
Where there is no apparent response to treatment, the diagnosis should
be re-evaluated. Dose increases may be
necessary.
Veterinarians should be aware that dogs with hyperadrenocorticism are
at increased risk of pancreatitis. This risk may
not diminish following treatment with trilostane.
1 capsule contains:
Active substance: Trilostane
10 mg
Excipients:
Titanium dioxide (E171)
0.942 mg
Ferric oxide (yellow) (E172)
0.035 mg
Ferric oxide (black) (E172)
0.532 mg
For a full list of excipients, see section 6.1.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_0_
_1_
_/_
_0_
_5_
_/_
_2_
_0_
_1_
_5_
_C_
_R_
_N_
_ _
_7_
_0_
_
                                
                                Lire le document complet
                                
                            

Rechercher des alertes liées à ce produit